SIGHT SCIENCES INC. - COMMON STOCK

Sight Sciences to Report First Quarter 2025 Financial Results on May 8, 2025

24 апр 2025 16:05:00 Источник Nasdaq GlobeNewswire

Sight Sciences Announces the Release of its Sustainability Report

23 апр 2025 16:05:00 Источник Nasdaq GlobeNewswire

Sight Sciences Appoints Gary Burbach to its Board of Directors

22 апр 2025 16:04:59 Источник Nasdaq GlobeNewswire

Sight Sciences to Debut OMNI® Edge Surgical System at the 2025 ASCRS Annual Meeting, Expanding the OMNI Product Portfolio

21 апр 2025 16:05:00 Источник Nasdaq GlobeNewswire

Sight Sciences to Present at the 24th Annual Needham Healthcare Conference on April 8th

25 мар 2025 16:05:00 Источник Nasdaq GlobeNewswire

Sight Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Initiates Full Year 2025 Financial Guidance

05 мар 2025 16:05:00 Источник Nasdaq GlobeNewswire

Sight Sciences to Present Comprehensive Clinical Data on the OMNI® Surgical System at the 2025 American Glaucoma Society Annual Meeting

24 фев 2025 16:05:00 Источник Nasdaq GlobeNewswire

Sight Sciences to Report Fourth Quarter and Full Year 2024 Financial Results on March 5, 2025

19 фев 2025 16:05:00 Источник Nasdaq GlobeNewswire

Sight Sciences to Present at Citi’s 2025 Unplugged MedTech and Life Sciences Access Day

13 фев 2025 16:05:00 Источник Nasdaq GlobeNewswire

Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2024 Financial Highlights

14 янв 2025 08:00:00 Источник Nasdaq GlobeNewswire

Sight Sciences Announces Real-World 36-Month Study Confirming Long-Term Effectiveness of Standalone OMNI Surgical System in Managing Primary Open-Angle Glaucoma

07 янв 2025 16:05:00 Источник Nasdaq GlobeNewswire

Sight Sciences Announces the Results of a Budget Impact Analysis for its TearCare® System for the Treatment of Meibomian Gland Disease (“MGD”) Showing Cost Savings Over Existing Reimbursed Treatment Options

19 дек 2024 16:05:00 Источник Nasdaq GlobeNewswire

Sight Sciences to Present at the Piper Sandler 36th Annual Healthcare Conference

19 ноя 2024 16:05:00 Источник Nasdaq GlobeNewswire

Sight Sciences Reports Third Quarter 2024 Financial Results and Updates its Full Year 2024 Adjusted Operating Expense Guidance

07 ноя 2024 16:05:01 Источник Nasdaq GlobeNewswire

Sight Sciences Appoints MK Raheja as Executive Vice President, Research and Development and Brenton Taylor as Executive Vice President, Operations

07 ноя 2024 16:04:00 Источник Nasdaq GlobeNewswire

Sight Sciences to Report Third Quarter Financial Results on November 7, 2024

17 окт 2024 16:05:00 Источник Nasdaq GlobeNewswire

Single TearCare® Treatment Improved Functional Visual Outcomes as well as Signs and Symptoms of Patients with Dry Eye Disease in Investigator-Initiated Trial

14 окт 2024 16:05:00 Источник Nasdaq GlobeNewswire

Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference

20 авг 2024 16:05:00 Источник Nasdaq GlobeNewswire

Sight Sciences Reports Second Quarter 2024 Financial Results and Narrows Full Year 2024 Financial Guidance

01 авг 2024 16:05:00 Источник Nasdaq GlobeNewswire

Sight Sciences to Report Second Quarter Financial Results on August 1, 2024

18 июл 2024 16:05:00 Источник Nasdaq GlobeNewswire